Cargando…

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful personalized therapeutic agents showing dramatic preclinical and clinical results, particularly in hematological malignancies. Ectopically expressed chimeric antigen receptors (CARs) reprogram immune cells to ta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Celichowski, Piotr, Turi, Marcello, Charvátová, Sandra, Radhakrishnan, Dhwani, Feizi, Neda, Chyra, Zuzana, Šimíček, Michal, Jelínek, Tomáš, Bago, Juli Rodriguez, Hájek, Roman, Hrdinka, Matouš
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015723/ https://www.ncbi.nlm.nih.gov/pubmed/36922828 http://dx.doi.org/10.1186/s12967-023-04041-6

Ejemplares similares

A Bird’s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers
por: Motais, Benjamin, et al.
Publicado: (2020)

Intercellular Mitochondrial Transfer in the Tumor Microenvironment
por: Sahinbegovic, Hana, et al.
Publicado: (2020)

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma
por: Vdovin, Alexander, et al.
Publicado: (2022)

PB2397: TRANSCRIPTOME ANALYSIS OF DIFFUSE LARGE B-CELL LYMPHOMA CELLS EXPRESSING MYD88 L265P REVEALS CD44, LGALS3, NFKBIZ AND BATF AS DOWNSTREAM TARGETS OF ONCOGENIC NF-ΚB SIGNALING.
por: Turi, Marcello, et al.
Publicado: (2023)

Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling
por: Turi, Marcello, et al.
Publicado: (2023)

Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment
por: Motais, Benjamin, et al.
Publicado: (2021)

Cytomorphology of Chimeric Antigen Receptor T-Cells (CAR-T)
por: Galli, Eugenio, et al.
Publicado: (2021)

Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness
por: Chen, Jian, et al.
Publicado: (2023)

Chimeric Antigen Receptor beyond CAR-T Cells
por: Qin, Vicky Mengfei, et al.
Publicado: (2021)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine
por: Zátopková, Martina, et al.
Publicado: (2022)

Novel Local “Off-the-Shelf” Immunotherapy for the Treatment of Myeloma Bone Disease
por: Charvátová, Sandra, et al.
Publicado: (2023)

Tuning the performance of CAR T cell immunotherapies
por: Richardson, Noah H., et al.
Publicado: (2019)

convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting
por: Landgraf, Kyle E., et al.
Publicado: (2020)

P805: EXTRAMEDULLARY MULTIPLE MYELOMA: MOLECULAR PATHOGENESIS AND NOVEL THERAPEUTIC TARGETS
por: Zihala, David, et al.
Publicado: (2023)

Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
por: Yoon, Dok Hyun, et al.
Publicado: (2018)

The Effects of Chimeric Antigen Receptor (CAR) Hinge Domain Post-Translational Modifications on CAR-T Cell Activity
por: Hirobe, Sachiko, et al.
Publicado: (2022)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

Dynamic fine-tuning of CAR-T cell therapy
por: Trehin, Pierre V.M., et al.
Publicado: (2023)

Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells
por: Darowski, Diana, et al.
Publicado: (2019)

Metabolic and Mitochondrial Functioning in Chimeric Antigen Receptor (CAR)—T Cells
por: Rad S. M., Ali Hosseini, et al.
Publicado: (2021)

The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Chimeric-Antigen-Receptor (CAR) T Cells and the Factors Influencing their Therapeutic Efficacy
por: Kravets, Victoria G, et al.
Publicado: (2017)

Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy
por: Sridhar, Praveen, et al.
Publicado: (2017)

Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting
por: Sutherland, Ashley R., et al.
Publicado: (2020)

Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
por: Brown, Kevin, et al.
Publicado: (2021)

Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy
por: Staudt, Ross E, et al.
Publicado: (2022)

Special Chimeric Antigen Receptor (CAR) Modifications of T Cells: A Review
por: Miao, Lele, et al.
Publicado: (2022)

CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
por: Taneja, Alankrita, et al.
Publicado: (2021)

Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
por: Gajra, Ajeet, et al.
Publicado: (2022)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

CAR-NK Cells: A Chimeric Hope or a Promising Therapy?
por: Sabbah, Mohamad, et al.
Publicado: (2022)

Price and Prejudice? The Value of Chimeric Antigen Receptor (CAR) T-Cell Therapy
por: Choi, Gyeyoung, et al.
Publicado: (2022)

Non-viral chimeric antigen receptor (CAR) T cells going viral
por: Balke-Want, H., et al.
Publicado: (2023)

1105. The Burden of Infections Prior to Chimeric Antigen Receptor (CAR) Modified T-cell Therapy Predicts Post-CAR T-cell Infectious Complications
por: Garner, Will, et al.
Publicado: (2020)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Chimeric antigen receptor (CAR)+ T cell selection method affects transgene efficacy
por: Rushworth, David, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8997vupft9b1291lioula9ne0j